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AbstrAct
Introduction Preterm birth accounts for more than 
85% of all perinatal complications and deaths. Seventy-
five per cent of early preterm births (EPTBs) occur 
spontaneously and without identifiable risk factors. 
The need for a broadly applicable, effective strategy 
for primary prevention is paramount. Secondary 
outcomes from the docosahexaenoic acid (DHA) to 
Optimise Mother Infant Outcome trial showed that 
maternal supplementation until delivery with omega-3 
(ω-3) long chain polyunsaturated fatty acid (LCPUFA), 
predominantly as DHA, resulted in a 50% reduction in 
the incidence of EPTB and an increase in the incidence 
of post-term induction or post-term prelabour caesarean 
section due to extended gestation. We aim to determine 
the effectiveness of supplementing the maternal diet 
with ω-3 LCPUFA until 34 weeks’ gestation on the 
incidence of EPTB.
Methods and analysis This is a multicentre, parallel 
group, randomised, blinded and controlled trial. Women 
less than 20 weeks’ gestation with a singleton or multiple 
pregnancy and able to give informed consent are eligible 
to participate. Women will be randomised to receive 
high DHA fish oil capsules or control capsules without 
DHA. Capsules will be taken from enrolment until 34 
weeks’ gestation. The primary outcome is the incidence 
of EPTB, defined as delivery before 34 completed weeks’ 
gestation. Key secondary outcomes include length of 
gestation, incidence of post-term induction or prelabour 
caesarean section and spontaneous EPTB. The target 
sample size is 5540 women (2770 per group), which will 
provide 85% power to detect an absolute reduction in 
the incidence of preterm birth of 1.16% (from 2.45% to 
1.29%) between the DHA and control group (two sided 
α=0.05). The primary analysis will be based on the 
intention-to-treat principle.
trial registration number Australia and New Zealand 
Clinical Trial Registry Number: 2613001142729; Pre-
results.
IntroductIon
background
Preterm birth, or birth before 37 completed 
weeks of pregnancy, is the leading cause of 
death in newborns, accounting for more 
than 85% of all perinatal complications and 
death.1 It is estimated that 10% of births 
(13 million babies each year worldwide) are 
preterm and 20% of these preterm births 
occur before 34 weeks, these being referred 
to as early preterm birth (EPTB). It is EPTB 
that is the major cause of perinatal mortality, 
serious neonatal morbidity and moderate 
to severe childhood disability in developed 
countries.2–4 Effective, broadly applicable 
primary prevention strategies to reduce the 
risk of EPTB are lacking.
Prostaglandins and other lipid mediators 
derived from omega-6 (ω-6) and omega-3 
(ω-3) fatty acids play essential roles in normal 
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Protocol
strengths and limitations of this study
 ► This study is the largest randomised controlled trial 
with adequate power that is designed to assess the 
effect of omega-3 (ω-3) long chain polyunsaturated 
fatty acid (LCPUFA) supplementation in pregnancy 
on the incidence of early preterm birth (EPTB) as the 
primary outcome.
 ► The study uses an innovative intervention strategy, 
which is unique compared with other trials in this 
field. The intervention targets the period before and 
during the time when EPTB is likely to occur and it is 
ceased at 34 weeks’ gestation, at which time EPTB 
has been prevented. This strategy may reduce the 
risk of post-term birth.
 ► The study assesses maternal LCPUFA status at 
baseline and at the end of the intervention period, 
providing an independent biomarker of compliance, 
in addition to maternal self-report and capsule back 
count.
 ► The study is conducted in an industrialised setting 
where intake of ω-3 LCPUFA is low. Findings from 
this study may not be applicable in populations with 
high intake of ω-3 LCPUFA.
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and pathologic initiation of labour.5 6 The fetoplacental 
unit is supplied with long chain polyunsaturated fatty 
acids (LCPUFA) from the maternal circulation, which is 
influenced by maternal LCPUFA intake and endogenous 
synthesis. Prostaglandins derived from ω-6 arachidonic 
acid are countered by those derived from ω-3 LCPUFA 
within the same tissues. The balance between the metab-
olites of ω-3 and ω-6 fatty acids plays an important role 
in the maintenance of normal gestation length and is a 
critical element in cervical ripening and the initiation of 
labour.7 If local production of ω-6 derived prostaglandins 
within the fetoplacental unit is too high, or local accumu-
lation of ω-3 LCPUFA is too low, the cervix may prema-
turely ripen and uterine contractions increase, which may 
in turn lead to preterm birth or EPTB.
Current Western diets are low in ω-3 LCPUFA.8 The 
Suppl 20 WHO recommends an intake of 300 mg/day of 
ω-3 LCPUFA for pregnant women; however, the median 
intake in Australian women of childbearing age is only 
29 mg/day9 compared with 1000 mg/day in women 
from nations with high-fish consumption such as Japan, 
Korea and Norway. The intake of ω-3 LCPUFA is further 
reduced among pregnant women due to a reduced 
intake of all fish following advisories for pregnant women 
to avoid specific long-lived predatory fish due to the 
concern about mercury contamination.10 The level of ω-3 
LCPUFA intake estimated to achieve normal rises in the 
fetoplacental unit for the maintenance of a full-term preg-
nancy is well above the intake of many pregnant women, 
highlighting a potential insufficiency for the uterus and 
fetoplacental unit. Optimising ω-3 LCPUFA intake in 
pregnancy may restore the balance between ω-3 and ω-6 
fatty acids and reduce the risk of preterm birth.
At the time the trial started, only two of the six included 
trials in the Cochrane review11 of marine oil supple-
mentation in pregnancy reported the effect on EPTB. 
Both trials12 13 were conducted in high-risk pregnancies 
designed to assess the effect of ω-3 LCPUFA supplemen-
tation to prevent reoccurrence of intrauterine growth 
restriction, preterm birth or pregnancy induced hyper-
tension. From these two relatively small trials (total of 
860 women), it was seen that women allocated to receive 
fish oil had a lower risk of EPTB compared with control 
(relative risk (RR) 0.69, 95% CI 0.49 to 0.99). Systematic 
reviews11 14 15 have shown no difference in the incidence of 
antepartum hospitalisation, caesarean section, eclampsia 
or other serious maternal morbidity between treatment 
(ω-3 LCPUFA supplements) and control groups. The RR 
of miscarriage, stillbirth and neonatal death also did not 
differ between the groups.11 14 15 None of the included 
trials reported the effect of ω-3 LCPUFA supplementation 
on EPTB in the general population of pregnant women.
The strongest evidence to support the efficacy of ω-3 
LCPUFA supplementation to reduce EPTB comes from 
our docosahexaenoic acid (DHA) to Optimise Mother 
Infant Outcome (DOMInO) trial,16 the largest trial to 
date of ω-3 LCPUFA supplementation in pregnancy. 
DOMInO was designed to assess the effect of ω-3 LCPUFA 
supplementation during the last half of pregnancy on 
the prevalence of postnatal depression in women and 
on early childhood neurodevelopmental outcomes. We 
enrolled 2399 women from five perinatal centres around 
Australia who were randomly assigned to receive identical 
looking capsules containing either fish oil concentrate 
(900 mg ω-3 LCPUFA/day) or a blend of vegetable oils 
(no ω-3 LCPUFA) from 20 weeks’ gestation until birth. In 
a prespecified secondary analysis, there were fewer EPTB 
in the ω-3 LCPUFA supplemented group compared 
with control (1.09% vs 2.25%, adjusted RR 0.49, 95% CI 
0.25 to 0.94, p=0.03) and fewer admissions to level three 
intensive care (1.75% vs 3.08%, RR 0.57, 95% CI 0.34 to 
0.97, p=0.04). Similar findings were reported in a smaller 
US trial (n=301), the Kansas University DHA Outcomes 
(KUDOS) Study,17 which showed that supplementation 
with 600 mg of DHA daily from mid-pregnancy until birth 
resulted in a reduction in the incidence of EPTB (0.6% 
vs 4.8%, p=0.025). The effect of DHA supplementation 
in pregnancy in lowering the risk of EPTB observed 
in both the DOMInO and KUDOS trials is consistent 
with the Cochrane review18 published before these two 
trials. Despite these encouraging findings, results have 
been viewed with caution by researchers and clinicians 
because EPTB was a secondary outcome of the DOMInO 
and KUDOS trials. A recent update to this Cochrane 
review (publication pending) includes 54 randomised 
trials with a total of >15 000 participants. Results show a 
clear reduction in EPTB (RR 0.61, 95% CI 0.46 to 0.81; 9 
randomised controlled trials (RCTs); n=4351) for supple-
mentation compared with placebo.19 Our DOMInO trial 
supports the safety data from previous systematic reviews; 
however, there were more post-term births requiring 
obstetric intervention (induction or caesarean section) 
in the ω-3 LCPUFA supplemented group compared with 
control (17.59% vs 13.72%, adjusted RR 1.28, 95% CI 1.06 
to 1.54, p=0.01). To determine both efficacy and safety 
of this intervention, we therefore plan to undertake a 
further trial with adequate power to assess the effect of 
ω-3 LCPUFA supplementation in pregnancy on EPTB as 
the primary outcome, with a unique design ceasing the 
intervention at 34 weeks’ gestation to reduce the risk of 
post-term birth.
Hypotheses
Optimising ω-3 LCPUFA intake in pregnancy will lead to 
lower risk of EPTB.
MetHods
trial design
The ORIP trial is designed as a randomised, controlled, 
clinician, researcher and participant/family blinded, 
multicentre trial with two parallel groups and a primary 
outcome of incidence of EPTB, defined as delivery before 
34 completed weeks’ gestation.
Participating centres
The sponsoring institution and Trial Coordinating Centre 
is the South Australian Health and Medical Research 
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Institute based at the Women’s and Children’s Hospital, 
Adelaide, South Australia. The trial is being conducted 
in the following six centres in Australia: Women’s & 
Children’s Hospital, Flinders Medical Centre and Lyell 
McEwin Hospital in South Australia; Joondalup Health 
Campus, Western Australia; Werribee Mercy Hospital, 
Werribee, Victoria and Mater Mothers Hospital, Brisbane, 
Queensland.
study population
Participants are pregnant women less than 20 weeks’ 
gestation.
eligibility criteria
Pregnant women are approached by trained clinical trial 
personnel in the antenatal clinic of participating centres.
Inclusion criteria
Women must meet both the following criteria to be 
enrolled in this study:
 ► Singleton or multiple pregnancy and less than 20 
weeks’ gestation.
 ► Able to give informed consent.
Exclusion criteria
Women must not have any of the following criteria to be 
enrolled in this study:
 ► Fetus with a known abnormality.
 ► Taking dietary supplements containing LCPUFA 
>150 mg/day.
 ► Taking dietary supplements containing LCPUFA 
<150 mg/day and are not willing to stop.
 ► Bleeding disorders where fish oil is contraindicated or 
on anticoagulant therapy.
 ► History of drug or alcohol abuse.
study treatments
Participating women will be randomised to high-DHA fish 
oil capsules or vegetable oil capsules. The study capsules 
are identical in colour, size, shape and packaging and 
are iso-caloric. Women will be asked to consume three 
capsules per day.
DHA capsules
Each 500 mg DHA enriched fish oil capsule contains 
approximately 300 mg of ω-3 LCPUFA. Women will be 
asked to take three capsules per day orally, which will 
provide approximately 1 g of ω-3 LCPUFA (800 mg of 
DHA and 100 mg of eicosapentaenoic acid per day. The 
remaining portion of oil consists of monounsaturated 
and saturated fatty acids.
Control capsules
The control capsules (also 500 mg in weight) contain a 
blend of vegetable oils (canola, sunflower and palm oils) 
with a trace of tuna oil (12.6 mg ω-3 LCPUFA) to assist 
with blinding. This blend of oil matches the fatty acid 
composition of the typical Australian diet.
Manufacture of study capsules
The active and control capsules are manufactured in a 
licensed facility (licensed according to the Code of Good 
Manufacturing Practice (GMP)) and have been donated 
to the trial by Efamol Ltd/Wassen International Ltd. The 
capsules are packaged and labelled in accordance with 
GMP including an individual product identifier (ID), 
batch number, expiry date and the statement ‘for clin-
ical trial use only’. The pharmacist or the investigator’s 
designee maintains accurate records of the receipt of all 
study capsules, including dates of receipt. Unused study 
capsules will be destroyed in compliance with applicable 
regulations.
Monitoring adherence to study treatment
Research personnel in each centre will maintain regular 
contact with participating women to monitor and 
encourage capsule adherence and study compliance and 
answer any questions as they arise. Women are asked to 
return unused capsules at the final study visit (34 weeks’ 
gestation) and the proportion of capsules returned serves 
as an additional measure of compliance. A finger prick 
blood specimen collected from the woman at this final 
visit will be used in fatty acid analysis as an independent 
biomarker of adherence. All clinical care for women 
involved in this trial will be undertaken by her designated 
obstetric/midwifery care provider.
outcome measures
The primary outcome of this trial is the incidence of EPTB, 
defined as delivery before 34 completed weeks’ gestation. 
Gestational age (GA) in days at delivery for primary and 
secondary outcomes will be determined from the esti-
mated date of delivery (EDD) using the equation (280 
– (EDD – date of birth)). EDD will be determined using 
a combination of maternal menstrual dating and ultra-
sound dating in accordance with established obstetric 
practice, as outlined in figure 1.
Key secondary outcomes
 ► Length of gestation
 ► Post-term induction or post-term prelabour caesarean 
section
 ► Preterm birth (<37 completed weeks)
 ► Spontaneous EPTB
 ► Birth weight
 ► Low birth weight (<2500 g)
 ► Admission to Neonatal Intensive Care Unit
 ► Perinatal death (stillbirth and death within first 28 
days of birth)
Other outcomes
 ► Spontaneous preterm birth, prelabour rupture 
of membranes, prelabour, preterm rupture of 
membranes.
 ► Birth length, birth head circumference, small for GA, 
very small for GA, large for GA, very large for GA.
 ► The length of hospital stay of infants and mothers, 
length of admission in Neonatal Intensive Care Unit.
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Figure 1 Flow chart for determining EDD. EDD, estimated date of delivery; GA, gestational age; LMP, last menstrual period; 
U/S ultrasound; w, weeks.
 ► Pregnancy and labour outcomes including gesta-
tional diabetes, pregnancy-induced hypertension, 
pre-eclampsia, eclampsia, maternal use of antibiotics, 
caesarean section, estimated blood loss at birth and 
postpartum haemorrhage.
 ► Incidence of serious adverse event (SAE) defined as 
maternal, neonatal or fetal deaths (stillbirth); fetal loss 
(miscarriage); maternal admissions to intensive care; 
admissions to intensive care for infants born after 34 
weeks’ gestation and major congenital anomalies.
 ► Neonatal complications including jaundice (requiring 
phototherapy), hypoglycaemia (requiring intravenous 
dextrose infusion), neonatal convulsion, brain injury 
(including intraventricular haemorrhage), retinop-
athy of prematurity, sepsis, necrotising enterocolitis 
and duration of supplemental oxygen. The defini-
tions and classifications of these neonatal complica-
tions are in accordance with the Australian and New 
Zealand Neonatal Network Data Dictionary.20
 ► Other side effects and tolerability of DHA supple-
mentation assessed through data collected in the case 
report form (CRF).
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Figure 2 ORIP trial schedule. **–t1=<20 weeks’ gestation; t1=2 weeks’ post-randomisation and allocation; t2=28 weeks’ 
gestation; t3=34 weeks’ gestation or birth, whichever occurs first; tx=6 weeks post-estimated due date. ω-3 LCPUFA, omega-3 
long chain polyunsaturated fatty acid.
Participant timeline
Women will be randomised and commence study treat-
ment capsules from enrolment (<20 weeks’ gestation) 
until 34 weeks’ gestation or birth, whichever occurs first. 
At enrolment, following informed consent and prior to 
commencement of study treatment, research personnel 
will collect a finger prick blood sample for baseline 
fatty acid status. The woman’s height and weight will be 
measured and baseline clinical and demographic data 
collected. Research personnel will contact the participant 
2 weeks following the enrolment visit and again when the 
woman is 28 weeks’ gestation to ascertain capsule adher-
ence and record adverse events. At 34 weeks’ gestation, 
participating women will attend a clinic appointment for 
collection of a finger prick blood sample for fatty acid 
analysis and unused capsules are returned and counted. 
Six weeks following delivery, research personnel will 
extract details of pregnancy, labour and birth from the 
woman and her baby’s medical records for primary and 
secondary outcome data; see figure 2 for a summary of 
the ORIP trial schema.
sample size
Our previous trial of DHA supplementation of preg-
nant women, the DOMInO trial,16 included women 
with singleton pregnancies and treatment resulted in a 
1.16% absolute reduction (from 2.25% to 1.09%) in the 
incidence of EPTB. This reduction occurred in the pres-
ence of non-adherence resulting from women assigned 
to the intervention failing to take the trial supplements 
as directed, and control women taking prenatal supple-
ments containing low dose ω-3 LCPUFA. Similar levels of 
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non-adherence are expected in the ORIP trial. Inclusion 
of women with multiple pregnancies in the ORIP trial is 
expected to result in a small increase in the incidence 
of EPTB in both treatment groups, since EPTB is more 
common in multiple pregnancies. To demonstrate an 
absolute reduction in the incidence of EPTB of 1.16% 
(from 2.45% to 1.29%) with 85% power and overall 
two-sided alpha=0.05 (alpha=0.049 at the final anal-
ysis), a sample size of 2631 per group (ie, 5262 total) is 
required. Allowing for a loss to follow-up of 5%, a total 
of 5540 women is required to ensure adequate power 
for the primary outcome. Since EPTB is a mother level 
outcome, the sample size calculations define the number 
of mothers that should be recruited and no adjustment 
for clustering due to multiple pregnancies is required for 
this outcome.
recruitment
Women will be approached to enter the trial by research 
staff at the time of attending their routine antenatal visit 
at one of the centres involved. Pregnant women will 
also be informed about the trial by display of approved 
advertising material which will be circulated in hard copy 
and via social media avenues. A participant information 
sheet describing the purpose of the study, the procedures 
to be followed and the risks and benefits of participa-
tion will be explained to interested women. Following 
a screening process to ensure inclusion and exclusion 
criteria are met, the investigator or nominee will conduct 
the informed consent discussion and will check that 
information provided is understood and answer any ques-
tions about the study. A record of all women screened and 
their enrolment status will be maintained to adhere to the 
consolidated standards for the reporting of randomised 
controlled trials.21 Women may withdraw their involve-
ment in the trial at any time and, wherever possible, the 
reason for withdrawal will be recorded.
randomisation procedures
Once the consent process has been documented by 
signing of the written consent form, the participant will 
be randomised using a web-based randomisation service. 
Stratification will be by centre and current supplement 
use (no LCPUFA vs ≤150 mg LCPUFA/day prior to 
randomisation). Allocation follows a computer-generated 
randomisation schedule with balanced variable blocks, 
prepared using  ralloc. ado V.3.7.5 in Stata V.12.1 by an 
independent statistician who is not involved with trial 
participants or data analysis. A unique six-digit study ID 
and a study pack with a unique product ID are assigned. 
The study ID identifies the randomised woman and the 
product ID identifies a pack of five bottles of either active 
or control capsules, prepackaged corresponding to the 
randomisation schedule.
blinding
Participants and their family, care providers, data collec-
tors, outcome assessors, research personnel and data 
analysts will all be blinded to randomisation group. The 
intervention and control capsules are identical in shape, 
size, colour, packaging and labelling and uniquely iden-
tified only by the product ID. In the DOMInO trial, we 
identified that more women in the intervention group 
correctly guessed their group allocation. We therefore 
added a small amount of tuna oil (5%) to the control 
capsules to enhance blinding of study participants. The 
randomisation code for an individual participant may be 
unblinded in an emergency if the site investigator decides 
a participant cannot be adequately treated without 
knowing their study treatment allocation. The principal 
investigator will be notified and must contact the Data 
Management and Analysis Centre, where the randomis-
ation list is securely stored. The time, date, study ID of 
the participant and reason for unblinding must be docu-
mented and events leading to the emergency unblinding 
will be recorded.
data collection and trial management
A purpose-built web-based clinical trial management 
information system (CTMS) with password protection and 
defined user-level access is used to facilitate trial manage-
ment. A record of all women approached, screened for 
eligibility and consented is recorded in real time in the 
CTMS. Once consented and randomised, the CTMS auto-
matically calculates study milestones for each participant. 
This information is readily available for clinical trial staff 
to enable scheduling of appointments and sample collec-
tion. Data entered by individual study centres is routinely 
scrutinised by the Coordinating Centre to monitor 
protocol adherence and study progress. Summary reports 
including screening data, enrolment, appointment atten-
dance, sample collection, SAEs and study completion 
are generated from the CTMS and reviewed at monthly 
trial steering committee meetings. Site monitoring visits 
to ensure compliance with good clinical practice and the 
study protocol are conducted at site start-up and then 
6 monthly or as required to ensure the integrity of the 
trial.
Data are collected by trained clinical trial staff at each 
participating centre onto carbon copy paper CRFs. 
Carbon copies of the completed CRF remain on site at 
participating centres with original copies being mailed to 
the Data Management and Analysis Centre at the Univer-
sity of Adelaide for data management including data entry 
and data cleaning. Data validity checks are completed 
by data entry personnel and data queries posted to the 
CTMS for resolution by participating centres. Data 
queries generated by statisticians during regular blinded 
reviews of data quality and batch checks are also managed 
through the CTMS. Electronic data are stored on secure 
servers at the Data Management and Analysis Centre and 
released only to persons authorised to receive those data. 
Following study completion, copies of study documents 
are retained at each study site or in archives. Documents 
held at the Coordinating Centre will be retained for at 
least 30 years after study completion in line with the 
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data retention schedules for research involving minors.22 
At the completion of this time, documentation will be 
destroyed using confidential document disposal. Elec-
tronic data will be stored indefinitely on secure servers 
with access only granted to authorised study personnel.
statistical methods
All participants will be analysed according to the group 
to which they were randomised (intention-to-treat prin-
ciple) for the primary analysis. The primary outcome 
of EPTB will be compared between intervention and 
control groups using a log binomial regression model. 
Adjustment will be made for the stratification variables 
centre and supplements, and results will be presented 
as a RR with CI and two-sided p value. Statistical signif-
icance will be assessed at an alpha of 0.049 to account 
for the prespecified interim analysis (see below) using 
the O'Brien-Fleming approach. Key secondary and other 
outcomes will be compared between treatment groups 
using log binomial regression models for binary outcomes 
and linear regression models for continuous outcomes 
with no adjustment for multiple comparisons. Clustering 
due to multiple pregnancies and repeat participation in 
the trial will be taken into account where applicable using 
generalised estimating equations. Secondary analyses will 
be performed for the primary outcome and related key 
secondary and other outcomes to test for evidence of 
effect modification by pregnancy status (single vs multiple 
pregnancy), history of preterm birth and baseline DHA. 
Missing data will be addressed using multiple imputation 
under a missing at random assumption. Sensitivity anal-
yses will be performed using the original unimputed data. 
A secondary per-protocol analysis will be performed for 
the primary outcome including only women who were 
compliant with the protocol. Two separate definitions of 
compliance will be used. First, women will be considered 
compliant if they returned their remaining capsules at the 
end of the trial and consumed at least 75% of the number 
of capsules expected to be consumed. Second, women 
will be considered compliant if they had the 28-week tele-
phone contact and reported they had missed less than 
7 capsules in the last week out of the recommended 21 
capsules.
All analyses will follow a prespecified statistical analysis 
plan. There is a single planned interim analysis of the 
primary outcome to be performed after data collection 
is complete for the first 50% of the target number of 
randomised participants.
data monitoring
An independent Data Monitoring Committee (DMC) 
has been set up to review the progress of the trial and 
provide feedback to the Trial Steering Committee. 
The DMC reviews general study progress (recruitment, 
compliance, loss to follow-up), the EPTB event rate and 
key secondary/safety outcomes. The committee meets 
annually or as required and consists of a neonatologist, 
obstetrician and statistician with clinical trials expertise. 
The DMC will be responsible for reviewing the results of 
the interim analysis.
An independent (blinded) SAE Committee has been 
established to review SAEs. There are no SAEs which 
would be anticipated as a unique consequence of partic-
ipation in the trial; however, all deaths, admissions to an 
intensive care unit of mothers or of infants born after 34 
completed weeks’ gestation and major congenital abnor-
malities are to be reported. The SAE Committee includes 
experts in obstetrics, neonatology, pathology and 
midwifery who are not involved in the trial. The primary 
role of the SAE Committee is to review all SAEs and deter-
mine whether there is any likelihood that involvement in 
the trial could have contributed to the event. Determi-
nations of causality will be made from medical records 
retrieved for this purpose. This committee meets quar-
terly or as required.
etHIcs And dIsseMInAtIon
research ethics approval
This protocol and the informed consent and participant 
information document have been approved by the Human 
Research Ethics Committee (HREC) of each study site. 
Women’s and Children’s Health Network HREC (Coor-
dinating HREC & Women’s and Children’s Hospital, 
Adelaide; Southern Adelaide Clinical HREC, Adelaide, 
South Australia); Mercy Health HREC (Werribee Mercy 
Hospital, Werribee, Victoria); Mater Mothers’ Hospital, 
Brisbane, Queensland; University of Notradame, Joon-
dalup Health Campus, Joondalup, Western Australia. Any 
subsequent modifications will be reviewed and approved 
by the HREC and governance of each study site. The 
study will be conducted in compliance with the current 
approved version of the protocol. Any change to the 
protocol document or informed consent form that affects 
the scientific intent, study design, patient safety or may 
affect a participant’s willingness to continue participa-
tion in the study will be considered a major amendment. 
All such amendments will be submitted to the HREC for 
approval. Any other changes to the protocol (such as 
administrative changes to dates and study personnel) will 
be considered minor amendments and will be notified to 
the HREC as appropriate. Study findings will be dissem-
inated via peer-reviewed publication, conference presen-
tations, informing participants with a lay summary and 
the wider community through social media.
confidentiality
Participant confidentiality is strictly held in trust by 
the participating investigators, research staff and their 
agents. This confidentiality is extended to cover testing 
of biological samples in addition to the clinical informa-
tion relating to participants. The study protocol, docu-
mentation, data and all other information generated will 
be held in strict confidence. No information concerning 
the study or the data will be released to any unautho-
rised third party, without prior written approval of the 
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Coordinating Centre. The Coordinating Centre and regu-
latory authorities may inspect all documents and records 
required to be maintained by the investigator, including 
but not limited to, medical records and pharmacy records 
for the infants in this study subject to individuals having 
obtained approval/clearance through State/National 
Governments and HREC as required by local laws. The 
study site will permit access to such records. Clinical infor-
mation will not be released without written permission of 
the parent/guardian, except as necessary for monitoring 
by HREC or regulatory agencies.
dissemination plan
Study findings will be submitted for peer-reviewed publi-
cation and for presentation at appropriate local and 
international conferences. In addition, study findings 
will be disseminated to participants through a one-page 
lay summary. Results will be made available to the wider 
community through social media avenues and the South 
Australian Health & Medical Research Institute website.
trial status
This enrolment phase of this trial completed on 27 April 
2017 with successful attainment of sample size (n=5544). 
Completion of study follow-up appointments and collec-
tion of labour and birth data from participant medical 
records will be completed by December 2017.
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